Insights

Merger & Acquisition Opportunity Harpoon Therapeutics was acquired by Merck Canada Inc. for $680 million, indicating a strong interest in immuno-oncology companies. Exploring partnerships with Merck post-acquisition could lead to new sales opportunities and collaborations.

Product Development Collaboration With a focus on developing T cell engagers for cancer treatment, Harpoon Therapeutics' innovative TriTAC® platform presents an opportunity for collaboration with other pharmaceutical companies looking to enhance their immuno-oncology product pipeline. Partnering for joint research or product development could open up new sales channels.

Tumor-Specific Treatment Focus Harpoon's ProTriTAC™ platform offers a unique approach of targeting tumors specifically, signaling potential interest from oncology centers and hospitals seeking advanced treatment options. Tailoring sales pitches to highlight tumor-specific treatments could attract healthcare institutions as potential clients.

Clinical Trial Data Insights The release of updated interim tolerability and response data from Harpoon's T cell engager clinical trials can be leveraged to showcase product efficacy and safety to healthcare professionals and oncologists. Sharing these data insights in presentations or conferences could generate interest and drive sales.

Employee Expansion Impact As Harpoon Therapeutics continues to hire key personnel like the Chief Legal Officer and Chief People Officer, the company is likely gearing up for growth. Identifying their expanding team structure and engaging with new executives could offer sales opportunities for service providers targeting pharmaceutical companies.

Harpoon Therapeutics Tech Stack

Harpoon Therapeutics uses 8 technology products and services including SiteCatalyst, SAS, OneTrust, and more. Explore Harpoon Therapeutics's tech stack below.

  • SiteCatalyst
    Analytics
  • SAS
    Business Intelligence
  • OneTrust
    Cookie Compliance
  • Culture Amp
    Human Resource Management System
  • New Relic
    Real User Monitoring
  • X-XSS-Protection
    Security
  • Adobe Tag Manager
    Tag Management
  • Acquia Cloud Site Factory
    Web Hosting

Media & News

Harpoon Therapeutics's Email Address Formats

Harpoon Therapeutics uses at least 1 format(s):
Harpoon Therapeutics Email FormatsExamplePercentage
flast@harpoontx.comJDoe@harpoontx.com
94%
firstlast@harpoontx.comJohnDoe@harpoontx.com
3%
last@harpoontx.comDoe@harpoontx.com
2%
last.first@harpoontx.comDoe.John@harpoontx.com
1%

Frequently Asked Questions

Where is Harpoon Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Harpoon Therapeutics's main headquarters is located at 611 Gateway Blvd. Suite 400 South San Francisco, California 94080 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Harpoon Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Harpoon Therapeutics's main corporate office by phone at +1-650-443-7400. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Harpoon Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Harpoon Therapeutics is a publicly traded company; the company's stock symbol is HARP.

What is Harpoon Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Harpoon Therapeutics's official website is harpoontx.com and has social profiles on LinkedIn.

How much revenue does Harpoon Therapeutics generate?

Minus sign iconPlus sign icon
As of May 2024, Harpoon Therapeutics's annual revenue reached $35M.

What is Harpoon Therapeutics's NAICS code?

Minus sign iconPlus sign icon
Harpoon Therapeutics's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Harpoon Therapeutics have currently?

Minus sign iconPlus sign icon
As of May 2024, Harpoon Therapeutics has approximately 59 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Financial Officer: W. P.Chief Medical Officer: L. W.Chief People Officer, Human Resources: W. C.. Explore Harpoon Therapeutics's employee directory with LeadIQ.

What industry does Harpoon Therapeutics belong to?

Minus sign iconPlus sign icon
Harpoon Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does Harpoon Therapeutics use?

Minus sign iconPlus sign icon
Harpoon Therapeutics's tech stack includes SiteCatalystSASOneTrustCulture AmpNew RelicX-XSS-ProtectionAdobe Tag ManagerAcquia Cloud Site Factory.

What is Harpoon Therapeutics's email format?

Minus sign iconPlus sign icon
Harpoon Therapeutics's email format typically follows the pattern of . Find more Harpoon Therapeutics email formats with LeadIQ.

How much funding has Harpoon Therapeutics raised to date?

Minus sign iconPlus sign icon
As of May 2024, Harpoon Therapeutics has raised $100M in funding. The last funding round occurred on Oct 23, 2023.

When was Harpoon Therapeutics founded?

Minus sign iconPlus sign icon
Harpoon Therapeutics was founded in 2015.
Harpoon Therapeutics

Harpoon Therapeutics

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For more information, please visit www.harpoontx.com.

Section iconCompany Overview

Headquarters
611 Gateway Blvd. Suite 400 South San Francisco, California 94080 US
Phone number
+1-650-443-7400
Stock Symbol
HARP
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2015
Employees
51-200

Section iconFunding & Financials

  • $100M

    Harpoon Therapeutics has raised a total of $100M of funding over 5 rounds. Their latest funding round was raised on Oct 23, 2023.

  • $10M$50M

    Harpoon Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $100M

    Harpoon Therapeutics has raised a total of $100M of funding over 5 rounds. Their latest funding round was raised on Oct 23, 2023.

  • $10M$50M

    Harpoon Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.